Customer Collaboration Drives Anju Future Product Innovations
Day 2 of the Anju Innovation Forum provided a comprehensive look at all the new feature and functionality innovations for capturing, distributing and managing the explosion of different data sets and sources that Anju is incorporating into future releases across its clinical, medical affairs and database product offerings. Deep customer interest and engagement with Anju was an overriding theme of the day with two client-driven sessions from Pfizer and Abbvie testifying to how Anju data capture and manipulation technology had taken clinical trial study build and execution as well as KOL profiling to the next level. The volume, sharpness and diversity of post-session questions further testified to how Anju has been listening to its customers’ asks and demonstrating its philosophy of creating solutions that are adaptive, and not disruptive, to their existing data tech systems environment.
- TrialOne will be rebranded to AnjuEPS and focus on making it the most robust early phase trial clinical study build solution on the market today; small changes that will have a big impact will include better security controls over participant study data, enhanced pharmacy, lab and logistics/sampling data collection management, and integration of early phase trial EDC with other Anju clinical data apps via AnjuBUS.
- Pfizer talked about how the COVID pandemic accelerated their work with Anju ta-Scan to create a layered intelligence model of expanded external data sources for predicting trial study site successful outcomes and a more efficient trial study pipeline flow overall.
- Anju’s continuing work in advancing identification, evaluation and capture of trusted clinical study source data from public domain registries, including language, semantic and other analytics to get the most accurate data profile of a clinical site study.
- Abbvie discussed how they are leveraging ta-Scan to assess real world data and trial sites, data variations of KOL trial investigator impacts in building study designs, ranking and scoring KOLs, and identification of rising star KOLs for future indication studies, resulting in expansion of ta-Scan to more than 400 users within their organization.
- New releases of PUBSTRAT will focus on more closely integrating with pharma MA function and make the publication planning process more insightful with enhanced data showing publication engagement, have greater utility and adaptability and will include innovative new features such as an abstract library, advanced intelligence search, updated publication approval module, and integration with AnjuDV and other Anju and non-Anju platforms.
- TrialMaster platform evolution will become more decentralized trial data-centric, including incorporating mHealth and device data, better UI for patient data entry experience, new coding and auto-coding functionality for compliance with clinical study language protocols, a unique-to-industry patient randomization simulator for accurate patient study and site selection.
- AnjuCTMS will evolve from a clinical study data management tool to a Risk Based Quality Management Platform (RBQM) that captures trial and site and overall study risk insights as well as flags issues as a study proceeds.
Day 2 put the spotlight on where the entire Anju product suite is heading and how the technology is being customized to address the growing data complexity challenges for customers. An exciting and final Day 3 of Anju Innovation Forum awaits…
If you want a recap on AIF Day 1, read on here.
For more information about Anju events, contact email@example.com